Stock-based Compensation (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2026 |
Dec. 31, 2025 |
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
| Schedule of Stock Option Activity |
No
stock options were granted or exercised during the three months ended March 31, 2026. The following table summarizes stock option activity
for the three months ended March 31, 2026:
Schedule of Stock
Option Activity
| | |
Number of Options | | |
Weighted- Average Exercise Price | | |
Weighted- Average Remaining Contractual Term (Years) | | |
Aggregate Intrinsic Value | |
| Outstanding — January 1, 2026 | |
| 33,858 | | |
$ | 17.67 | | |
| | | |
| - | |
| Forfeited, cancelled and expired | |
| (1,569 | ) | |
$ | 48.53 | | |
| | | |
| | |
| Outstanding — March 31, 2026 | |
| 32,289 | | |
$ | 16.17 | | |
| 5.54 | | |
$ | - | |
| Exercisable — March 31, 2026 | |
| 30,136 | | |
$ | 17.04 | | |
| 5.45 | | |
$ | - | |
|
No
stock options were granted during the years ended December 31, 2025, and 2024. The following table summarizes stock option activity for
the year ended December 31, 2025:
Schedule
of Stock Option Activity
| | |
Number of Options | | |
Weighted- Average Exercise Price | | |
Weighted- Average Remaining Contractual Term (Years) | | |
Aggregate Intrinsic Value | |
| Outstanding — January 1, 2025 | |
| 34,046 | | |
$ | 30.55 | | |
| | | |
| - | |
| Forfeited or expired | |
| (188 | ) | |
| 2,350.64 | | |
| | | |
| | |
| Outstanding — December 31, 2025 | |
| 33,858 | | |
| 17.67 | | |
| 5.72 | | |
$ | - | |
| Exercisable — December 31, 2025 | |
| 30,961 | | |
| 18.95 | | |
| 5.60 | | |
$ | - | |
|
| Schedule of Stock-based Compensation Expenses |
|
The
following table presents total stock-based compensation expense for the years ended December 31, 2025, and 2024:
Schedule
of Stock-based Compensation Expenses
| | |
2025 | | |
2024 | |
| | |
Year Ended December 31, | |
| | |
2025 | | |
2024 | |
| Research and development | |
$ | - | | |
$ | 149 | |
| General and administrative | |
| 25 | | |
| 362 | |
| Total stock-based compensation expense | |
$ | 25 | | |
$ | 511 | |
|
| Eos SENOLYTIXS Inc [Member] |
|
|
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
| Schedule of Stock Option Activity |
The
following is a summary of stock option activity under the stock option plans for the three months ended March 31, 2026:
Schedule
of Stock Option Activity
| | |
Number of
Shares | | |
Weighted
Average
Exercise Price | | |
Weighted
Average
Remaining
Contractual
Term | | |
Intrinsic
Value | |
| Outstanding as of December 31, 2025 | |
| 683,990 | | |
$ | 0.01 | | |
| 9.14 | | |
$ | - | |
| Granted | |
| 164,704 | | |
| 3.65 | | |
| | | |
| | |
| Exercised | |
| - | | |
| - | | |
| | | |
| | |
| Forfeited | |
| - | | |
| - | | |
| | | |
| | |
| Outstanding as of March 31, 2026 | |
| 848,694 | | |
$ | 0.72 | | |
| 9.07 | | |
$ | - | |
| Exercisable as of March 31, 2026 | |
| 49,435 | | |
$ | 0.01 | | |
| 8.74 | | |
$ | - | |
| Vested and expected to vest as of March 31, 2026 | |
| 848,694 | | |
$ | 0.72 | | |
| 9.07 | | |
$ | - | |
|
The
following is a summary of stock option activity under the stock option plans for the periods ended December 31, 2025 and 2024:
Schedule
of Stock Option Activity
| | |
Number of Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term | | |
Intrinsic Value | |
| Outstanding as of October 15, 2024 (date of inception) | |
| - | | |
$ | - | | |
| | | |
$ | - | |
| Granted | |
| 137,815 | | |
$ | 0.01 | | |
| | | |
| | |
| Exercised | |
| - | | |
$ | - | | |
| | | |
| | |
| Forfeited | |
| - | | |
$ | - | | |
| | | |
| | |
| Outstanding as of December 31, 2024 | |
| 137,815 | | |
$ | 0.01 | | |
| 9.97 | | |
$ | - | |
| | |
| | | |
| | | |
| | | |
| | |
| Granted | |
| 546,175 | | |
$ | 0.01 | | |
| | | |
| | |
| Exercised | |
| - | | |
$ | - | | |
| | | |
| | |
| Forfeited | |
| - | | |
$ | - | | |
| | | |
| | |
| Outstanding as of December 31, 2025 | |
| 683,990 | | |
$ | 0.01 | | |
| 9.14 | | |
$ | - | |
| Exercisable as of December 31, 2025 | |
| 34,450 | | |
$ | 0.01 | | |
| 8.97 | | |
$ | - | |
| Vested and expected to vest as of December 31, 2025 | |
| 683,990 | | |
$ | 0.01 | | |
| 9.14 | | |
$ | - | |
|
| Schedule of Grant-Date Fair Value of Stock Options |
The
following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the
grant-date fair value of stock options granted during the three months ended March 31, 2026 and 2025:
Schedule
of Grant-Date Fair Value of Stock Options
| | |
Three Months Ended March 31, | |
| | |
2026 | | |
2025 | |
| Risk-free interest rate | |
| 3.78 | % | |
| 4.25 | % |
| Expected term (in years) | |
| 5.62 | | |
| 9.83 | |
| Expected volatility | |
| 109.3 | % | |
| 112.3 | % |
| Expected dividend yield | |
| 0.00 | % | |
| 0.00 | % |
|
The
following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the
grant-date fair value of stock options granted during 2025 and 2024:
Schedule
of Grant-Date Fair Value of Stock Options
| | |
Year Ended December 31, | |
| | |
2025 | | |
2024 | |
| Risk-free interest rate | |
| 4.24 | % | |
| 4.41 | % |
| Expected term (in years) | |
| 9.7 | | |
| 6.1 | |
| Expected volatility | |
| 112.3 | % | |
| 113.4 | % |
| Expected dividend yield | |
| 0.00 | % | |
| 0.00 | % |
|